Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Question for the brainiacs.....
View:
Post by skier59 on Feb 16, 2022 1:24pm

Question for the brainiacs.....

what would it mean if that Group of the "Undertreated", came in with sthealer results, after their 6 month 2nd dose? Along with other fantastic results at the same time? Filling in that bar chart to the top. Wonder what that might do to the SP ?
Comment by menoalittle on Feb 16, 2022 3:26pm
>>  if that Group of the "Undertreated", came in with sthealer results, after their 6 month 2nd dose? please correct me if I'm wrong (could be my age, as that seems to be a popular reason here for posting incorrect info here... lol), but I thought I read somewhere that first batch of undertreated folk were dropped from the trial (and therefore, won't ever be ...more  
Comment by skier59 on Feb 16, 2022 4:08pm
I thought I read somewhere they would get the 2nd dose after 6 months. Which according to my calculations, they should have right now, I think a 90 day result due now, on a follow up to their 2nd treatment. This actually can be a very important data group, as for sure hospitals will screw up first treatments along the way. How effective is the 2nd dose after 6 months? Things that make you go ...more  
Comment by yureja on Feb 16, 2022 7:03pm
This post has been removed in accordance with Community Policy
Comment by O12009 on Feb 16, 2022 7:34pm
  I have read that they were removed from the trial. I have also read that we will see results from the 2nd treatment of those who were under treated. I also read that some were under treated for the second time. I'm all so confused but have never ask that question. we may need someone who knows what happen to the under treated.  
Comment by 99942Apophis on Feb 16, 2022 9:22pm
I thought the only ones removed from the first 12 were the 5 with no response leaving 7  and within that group had mostly partially response and I think 1 with complete response on the first treatment after that I also got confused and age has nothing to do with it. The confusion was because we didn't have Dr. Vera Madzarevic to present everything in a clear picture package, not funny but ...more  
Comment by floatinketucky on Feb 16, 2022 10:52pm
July 30, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers is pleased to provide an update on its Phase II Non-Muscle Invasive ...more  
Comment by floatinketucky on Feb 16, 2022 10:56pm
Looks like 8 of the First 12 from phase 2 are up for the 2nd treatment at full dose! 67% CR @ 18 months.  Patients removed after 24 moths from the study. Only the doc knows about the 24 .. but he diald back the first dozen to lower dose levels....
Comment by tdon1229 on Feb 16, 2022 10:56pm
  I can't see how a patient, not treated according to the protocol of the Phase II clinical trial (two instillations at the Therapeutic Dose 180 days apart), can be included in the formal results of that clinical trial.   Can they be included as additional information re safety and efficacy, similar to that regarding the Phase I patients?  Certainly, just not as part of ...more  
Comment by gossamer6 on Feb 17, 2022 12:03am
This post has been removed in accordance with Community Policy
Comment by Pandora on Feb 17, 2022 1:44am
The guys are out but the girls did it. Gold is coming back home! Cheers!
Comment by floatinketucky on Feb 16, 2022 10:49pm
I hate to go by memory but only maybee 4 or 5 of the first 12 were dropped?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250